Widespread monoclonal IgE antibody convergence to an immunodominant, pro-anaphylactic Ara h 2 epitope in peanut allergy

January 1, 2023
J Allergy Clin Immunol
https://pubmed.ncbi.nlm.nih.gov/37748654

This article is currently being updated. View its version on PubMed.

https://pubmed.ncbi.nlm.nih.gov/37748654

Research summary

This study investigates the immune response in individuals with peanut allergy, focusing on the convergence of monoclonal IgE antibodies to a specific epitope on the Ara h 2 protein, which is known to trigger anaphylactic reactions. The research aims to understand the molecular basis of this convergence and its implications for allergy diagnostics and therapeutics.

Key outcome of the study

The findings reveal that individuals with peanut allergy commonly produce IgE antibodies targeting a specific epitope on the Ara h 2 protein. Using the humanized mouse model, researchers demonstrated that IgE antibodies binding to this epitope could trigger severe systemic anaphylaxis, highlighting its potential as a therapeutic target.

Mouse model

Humanized IgE and FcεRI mouse model developed by genOway, in which the murine IgE and FcεRI genes are replaced with their human counterparts. This model enables the functional study of human IgE-mediated anaphylaxis in vivo.

TARGET:
IgE, Fcer1a
Immunoglobulin E, Fc epsilon receptor alpha

Keywords

Peanut allergy, IgE-mediated hypersensitivity, Anaphylaxis, Immunotherapy, FcεRI signaling

Technical specifications

Humanized Knockin mouse model, IgE-FcεRI axis, Anaphylaxis model, Passive sensitization, Epitope mapping

Related products

Catalogue product

genO‑hIgE/hFcεR1

Use the genO‑hIgE/hFcεR1 mouse model to successfully screen for innovative therapeutics for allergy, asthma and other IgE-mediated diseases.

Customized product

No items found.